Vestibular Migraine After Analgesics and NSAIDs Have Failed: What to Do Next

Not all vestibular migraine attacks respond adequately to first-line oral analgesics or NSAIDs. This protocol addresses the structured approach for attacks where initial therapy has not achieved the expected outcome.

Previous treatment — goal not reached

Oral analgesics and NSAIDs — including ASA, ibuprofen, metamizole, diclofenac potassium, combination analgesic preparations, and paracetamol/acetaminophen — did not achieve the expected reduction of migraine headache 2 hours after taking the medication.

Next-step approach (partial overview)

When vestibular migraine attacks are severe or unresponsive to analgesics and NSAIDs, a targeted class of acute therapy — 5-HT1B/1D receptor agonists — is indicated. The full protocol specifies which agents and under what conditions.

▶ Key clinical goal: pain-free after 2 hours.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/2514183X1882337

The 5-HT1B/1D-agonists (in alphabetical order) almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan are the substances with the best efficacy in acute migraine attacks and should be used in severe headache and in migraine attacks which are unresponsive to analgesics or NSAIDs.
Sumatriptan subcutaneous injection (6 mg) is the most effective therapy of acute migraine attacks.
If headache recurs after initial effectiveness of a triptan, a second dose of the triptan may not be given for at least 2 h.
Triptans are more effective than analgesics or NSAIDs for the endpoint ‘pain-free after 2 h’ in most randomized studies.

View source ↗